PT1021196E - Utilizacao de uma solucao de clorito quimicamente estabilizada para inibir uma resposta imunitaria especifica para antigenio - Google Patents
Utilizacao de uma solucao de clorito quimicamente estabilizada para inibir uma resposta imunitaria especifica para antigenioInfo
- Publication number
- PT1021196E PT1021196E PT98946681T PT98946681T PT1021196E PT 1021196 E PT1021196 E PT 1021196E PT 98946681 T PT98946681 T PT 98946681T PT 98946681 T PT98946681 T PT 98946681T PT 1021196 E PT1021196 E PT 1021196E
- Authority
- PT
- Portugal
- Prior art keywords
- antigen
- inhibit
- chloride solution
- response specific
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6095397P | 1997-10-06 | 1997-10-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1021196E true PT1021196E (pt) | 2004-06-30 |
Family
ID=22032774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT98946681T PT1021196E (pt) | 1997-10-06 | 1998-10-06 | Utilizacao de uma solucao de clorito quimicamente estabilizada para inibir uma resposta imunitaria especifica para antigenio |
Country Status (12)
Country | Link |
---|---|
US (4) | US20050129784A1 (pt) |
EP (1) | EP1021196B1 (pt) |
JP (1) | JP4369615B2 (pt) |
CN (1) | CN1152691C (pt) |
AT (1) | ATE258799T1 (pt) |
AU (1) | AU754928B2 (pt) |
CA (1) | CA2306273A1 (pt) |
DE (1) | DE69821506T2 (pt) |
DK (1) | DK1021196T3 (pt) |
ES (1) | ES2217582T3 (pt) |
PT (1) | PT1021196E (pt) |
WO (1) | WO1999017787A2 (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1408994A2 (en) * | 1999-08-18 | 2004-04-21 | OXO Chemie AG | Chemically-stabilized chlorite solutions for treating cancer |
US7105183B2 (en) | 2004-02-03 | 2006-09-12 | The Regents Of The University Of California | Chlorite in the treatment of neurodegenerative disease |
AU2011205095B2 (en) * | 2004-02-03 | 2014-07-03 | The Regents Of The University Of California | Chlorite in the treatment of neurodegenerative disease |
CA2919344C (en) | 2005-12-22 | 2017-02-28 | Neuraltus Pharmaceuticals, Inc. | Chlorite formulations, and methods of preparation and use thereof |
US8252343B2 (en) | 2007-06-01 | 2012-08-28 | Nuvo Research Ag | Use of WF10 for treating allergic asthma, allergic rhinitis and atopic dermatitis |
EP2461694A4 (en) * | 2009-08-06 | 2013-06-19 | Neuraltus Pharmaceuticals Inc | TREATMENT OF DISORDERS ASSOCIATED WITH MACROPHAGES |
US9266957B2 (en) | 2009-11-10 | 2016-02-23 | Mayo Foundation For Medical Education And Research | Methods and materials for treating renal cell carcinoma and glioblastoma multiforme |
CA2857604A1 (en) | 2011-12-22 | 2013-06-27 | Nuvo Research Gmbh | Liposomal chlorite or chlorate compositions |
WO2013109949A1 (en) * | 2012-01-19 | 2013-07-25 | Ibt Usa Inc. | Therapeutic uses of tetrachlorodecaoxygen (tcdo) |
US9970936B2 (en) | 2012-11-13 | 2018-05-15 | Mayo Foundation For Medical Education And Research | Methods and materials for assessing immune system profiles |
US10094835B2 (en) | 2013-05-09 | 2018-10-09 | Mayo Foundation For Medical Education And Research | Treating patients based on immune subtypes |
JP6900596B2 (ja) * | 2015-08-20 | 2021-07-07 | フリードリッヒ − ヴィルヘルム キューネ | 赤血球疾患およびそれによって媒介される症状を治療するための亜塩素酸塩の使用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4574084A (en) * | 1983-02-25 | 1986-03-04 | Peter Berger | Process for the preparation of a modified aqueous chlorite solution, the solution prepared by this process and the use thereof |
DE3515745A1 (de) * | 1985-05-02 | 1986-11-06 | Oxo Chemie GmbH, 6900 Heidelberg | Waessrige chloritmatrix-loesung |
DE3515749A1 (de) * | 1985-05-02 | 1986-11-06 | Oxo Chemie GmbH, 6900 Heidelberg | Verwendung einer stabilisierten chloritmatrixloesung bei infektioesen zustaenden |
US4851222A (en) * | 1988-01-27 | 1989-07-25 | Oxo Chemie Gmbh | Method of promoting regeneration of bone marrow |
US4956184A (en) * | 1988-05-06 | 1990-09-11 | Alcide Corporation | Topical treatment of genital herpes lesions |
DE4208828A1 (de) * | 1992-03-19 | 1993-09-23 | Oxo Chemie Gmbh | Verwendung einer chemisch stabilisierten chloritmatrix zur herstellung von arzneimitteln zur behandlung von hiv-infektionen |
US5830511A (en) * | 1992-06-25 | 1998-11-03 | Bioxy Inc. | Therapeutic, production and immunostimulatory uses of biocidal compositions |
US5877222A (en) * | 1996-07-19 | 1999-03-02 | The Regents Of The University Of California | Method for treating aids-associated dementia |
US8252343B2 (en) * | 2007-06-01 | 2012-08-28 | Nuvo Research Ag | Use of WF10 for treating allergic asthma, allergic rhinitis and atopic dermatitis |
-
1998
- 1998-10-06 CN CNB988118858A patent/CN1152691C/zh not_active Expired - Fee Related
- 1998-10-06 JP JP2000514658A patent/JP4369615B2/ja not_active Expired - Fee Related
- 1998-10-06 ES ES98946681T patent/ES2217582T3/es not_active Expired - Lifetime
- 1998-10-06 DK DK98946681T patent/DK1021196T3/da active
- 1998-10-06 AT AT98946681T patent/ATE258799T1/de active
- 1998-10-06 PT PT98946681T patent/PT1021196E/pt unknown
- 1998-10-06 DE DE69821506T patent/DE69821506T2/de not_active Expired - Lifetime
- 1998-10-06 CA CA002306273A patent/CA2306273A1/en not_active Abandoned
- 1998-10-06 EP EP98946681A patent/EP1021196B1/en not_active Expired - Lifetime
- 1998-10-06 WO PCT/IB1998/001676 patent/WO1999017787A2/en active IP Right Grant
- 1998-10-06 AU AU93642/98A patent/AU754928B2/en not_active Ceased
-
2004
- 2004-07-22 US US10/895,941 patent/US20050129784A1/en not_active Abandoned
-
2008
- 2008-06-04 US US12/132,761 patent/US20090004295A1/en not_active Abandoned
-
2010
- 2010-09-30 US US12/894,618 patent/US20110076344A1/en not_active Abandoned
-
2012
- 2012-02-06 US US13/366,595 patent/US20120141514A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DK1021196T3 (da) | 2004-06-07 |
ES2217582T3 (es) | 2004-11-01 |
JP2001518512A (ja) | 2001-10-16 |
US20120141514A1 (en) | 2012-06-07 |
WO1999017787A3 (en) | 1999-06-17 |
ATE258799T1 (de) | 2004-02-15 |
DE69821506T2 (de) | 2004-12-16 |
CN1306433A (zh) | 2001-08-01 |
CA2306273A1 (en) | 1999-04-15 |
AU754928B2 (en) | 2002-11-28 |
WO1999017787A2 (en) | 1999-04-15 |
US20110076344A1 (en) | 2011-03-31 |
US20090004295A1 (en) | 2009-01-01 |
US20050129784A1 (en) | 2005-06-16 |
EP1021196B1 (en) | 2004-02-04 |
AU9364298A (en) | 1999-04-27 |
DE69821506D1 (de) | 2004-03-11 |
JP4369615B2 (ja) | 2009-11-25 |
EP1021196A2 (en) | 2000-07-26 |
CN1152691C (zh) | 2004-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bloom et al. | Selective primary health care: strategies for control of disease in the developing world. V. Leprosy | |
Rook et al. | The pathogenesis of tuberculosis | |
Schwab et al. | Association of experimental chronic arthritis with the persistence of group A streptococcal cell walls in the articular tissue | |
PT1021196E (pt) | Utilizacao de uma solucao de clorito quimicamente estabilizada para inibir uma resposta imunitaria especifica para antigenio | |
ATE228373T1 (de) | Unterdrückung von autoimmunkrankheiten durch antigene in wartestellung | |
DE69939747D1 (de) | Verfahren von dna-impfung | |
FR12C0004I2 (fr) | Anticorps contre l'antigene ctla-4 humain et utilisation | |
IL132468A0 (en) | A kit for inducing immune response against a tumor or a disease caused by an infection agent | |
HUP9801560A1 (hu) | Szaponint és szterint tartalmazó vakcinák | |
ES2181676T3 (es) | Diagnosis y tratamiento de enfermedades autoinmunitarias. | |
ATE195875T1 (de) | Spezifische modulationen des immunsystems | |
LV12085A (lv) | Dendritiskas sunas stimulejosais faktors | |
DE69110877D1 (de) | Idiotypen-impfung gegen b-zell-lymphoma. | |
Brown | Molecular approaches to elucidating innate and acquired immune responses to Babesia bovis, a protozoan parasite that causes persistent infection | |
HK1025738A1 (en) | Lo-cd2a antibody and uses thereof for inhibiting tcell activation and proliferation | |
RU94045825A (ru) | Применение материала, полученного из mycobacterium vaccae для производства терапевтического средства для лечения психических заболеваний, способ лечения психических заболеваний, продукт, содержащий антигенный и/или иммунорегуляторный материал, фармацевтическое средство | |
Undeen et al. | Nosema algerae: infection of the white mouse by a mosquito parasite | |
Burns et al. | Immunology and infectious disease | |
Safai et al. | Immunodermatology | |
Mehra et al. | Induction of cell-mediated immunity to Mycobacterium leprae in guinea pigs | |
ATE164311T1 (de) | Orale, pharmazeutische zusammensetzungen das ein protein oder peptide, eine antikoerper und polymerkugeln enthalten | |
Levitt et al. | The immunobiology of Chlamydia | |
HUP9800613A2 (hu) | Humán Fas-antigén elleni humanizált antitest | |
YU40796A (sh) | Preparati i postupci za tretiranje obolenja koja izazivaju t ćelije | |
Junqueira-Kipnis et al. | Live vaccines have different NK cells and neutrophils requirements for the development of a protective immune response against tuberculosis |